Luis Prieto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luis Prieto has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Carmen Carazo-Díaz
Universidad Católica de Murcia, Murcia, España
3 shared publications - Vivencio Barrios
Department of Cardiology, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, 28034 Madrid, Spain
3 shared publications Diego Vargas
High Resolution Hospitalization Unit, Hospital el Toyo, Hospital de Poniente El Ejido, Almeria, Spain
2 shared publicationsJose Polo
Primary Care Health Center Casar de Cáceres, Cáceres, Spain
2 shared publicationsCarlos Escobar
Cardiology Department, University Hospital La Paz, Madrid, Spain
1 shared publication- Carlos Escobar
Servicio de Cardiología, Hospital Universitario La Paz, Madrid, España
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by IMR Press in Revista De Neurologia
- Vol. 81 (6) , 52643
Statistical Inference in Database Exploitation: Sample Size and Confounding Factors
Database (DB) exploitation is an essential tool in medical and epidemiological research, enabling the extraction of hidden insights from large volumes of information through statistical analysis. This work provides a methodological reflection on two critical aspects of such studies, namely sample size and confounder detection via multivariate analysis. When working with databases, researchers must perform statistical inference based exclusively on the available data and therefore often ask whether the fixed sample size is sufficient to detect relationships of interest. In most cases, no threshold value separates valid sizes from invalid ones, as statistical power increases gradually and depends on multiple parameters, with no fixed cutoff points. Even when the results are inconclusive (high p-values), possibly because of limited sample size, their publication is essential to feed future meta-analyses that may provide more solid conclusions. DB analysis requires discriminating between general and circumstantial associations. Although the relationships revealed by univariate analysis maintain their descriptive value, the accuracy of their interpretation can be increased by identifying possible confounding factors.
- 30 June 2026
- Published by IMR Press in Revista De Neurologia
- Vol. 81 (6) , 52643
Open AccessStatistical Inference in Database Exploitation: Sample Size and Confounding Factors
Database (DB) exploitation is an essential tool in medical and epidemiological research, enabling the extraction of hidden insights from large volumes of information through statistical analysis. This work provides a methodological reflection on two critical aspects of such studies, namely sample size and confounder detection via multivariate analysis. When working with databases, researchers must perform statistical inference based exclusively on the available data and therefore often ask whether the fixed sample size is sufficient to detect relationships of interest. In most cases, no threshold value separates valid sizes from invalid ones, as statistical power increases gradually and depends on multiple parameters, with no fixed cutoff points. Even when the results are inconclusive (high p-values), possibly because of limited sample size, their publication is essential to feed future meta-analyses that may provide more solid conclusions. DB analysis requires discriminating between general and circumstantial associations. Although the relationships revealed by univariate analysis maintain their descriptive value, the accuracy of their interpretation can be increased by identifying possible confounding factors.
- Open Access
- 27 November 2025
- Published by IMR Press in Revista De Neurologia
- Vol. 80 (10) , 43204
Case-Control Studies: Potential Savings in Time and Resources, and Potential Gain in Statistical Power
Although prospective studies directly estimate the influence of a factor on the onset of a disease, case-control sampling is often cheaper, faster, and sometimes the only feasible option. In these studies, a random sample of individuals with the disease (cases) is taken, and the proportion of them, P1, who were exposed to the factor is evaluated. A random sample of individuals without the disease (controls) is also taken, and the proportion of them, P0, who were exposed is evaluated. From these two proportions, the respective odds and their ratio, the odds ratio (OR), are calculated. When the incidence of the disease is small, say less than 10%, this OR value closely approximates the relative risk (RR), and therefore tells us, with good approximation, how much greater the risk of having the disease is if one is exposed to the factor. In all cases, case-control studies tend to have more confounding factors, which are not easily controllable, than prospective studies. However, under certain circumstances, they have a much higher statistical power than the prospective design.
- 27 November 2025
- Published by IMR Press in Revista De Neurologia
- Vol. 80 (10) , 43204
Open AccessCase-Control Studies: Potential Savings in Time and Resources, and Potential Gain in Statistical Power
Although prospective studies directly estimate the influence of a factor on the onset of a disease, case-control sampling is often cheaper, faster, and sometimes the only feasible option. In these studies, a random sample of individuals with the disease (cases) is taken, and the proportion of them, P1, who were exposed to the factor is evaluated. A random sample of individuals without the disease (controls) is also taken, and the proportion of them, P0, who were exposed is evaluated. From these two proportions, the respective odds and their ratio, the odds ratio (OR), are calculated. When the incidence of the disease is small, say less than 10%, this OR value closely approximates the relative risk (RR), and therefore tells us, with good approximation, how much greater the risk of having the disease is if one is exposed to the factor. In all cases, case-control studies tend to have more confounding factors, which are not easily controllable, than prospective studies. However, under certain circumstances, they have a much higher statistical power than the prospective design.
- Open Access
- 7 March 2025
- Published by IMR Press in Revista De Neurologia
- Vol. 80 (2) , 33481
Key Measures in Epidemiology: Risk Difference, Relative Risk and Odds Ratio
In epidemiology, the relative frequency of a disease is expressed as the proportion of individuals affected, typically expressed as a percentage, or per thousand individuals. Another important measure is the odds, which represents the ratio of affected individuals to unaffected individuals, calculated by dividing by the proportion of affected individuals by the proportion of unaffected individuals. To assess whether a specific factor increases or decreases the risk of disease, researchers compare the proportion of affected individuals in an exposed group (where the factor is present) with an unexposed group (where the factor is absent). This comparison can be quantified using three key measures: Risk Difference (RD): The absolute difference in disease risk between the exposed and unexposed groups. Relative Risk (RR): The ratio of disease risk in the exposed group to that in the unexposed group. Odds Ratio (OR): The ratio of the odds of disease in the exposed group to the odds in the unexposed group. While risk reflects the proportion of individuals affected within a population, odds represent the ratio of affected to unaffected individuals. The OR is particularly useful in case-control studies because it can approximate the RR when diseases are rare, providing valuable insights even when direct risk calculations are not feasible.
- 7 March 2025
- Published by IMR Press in Revista De Neurologia
- Vol. 80 (2) , 33481
Open AccessKey Measures in Epidemiology: Risk Difference, Relative Risk and Odds Ratio
In epidemiology, the relative frequency of a disease is expressed as the proportion of individuals affected, typically expressed as a percentage, or per thousand individuals. Another important measure is the odds, which represents the ratio of affected individuals to unaffected individuals, calculated by dividing by the proportion of affected individuals by the proportion of unaffected individuals. To assess whether a specific factor increases or decreases the risk of disease, researchers compare the proportion of affected individuals in an exposed group (where the factor is present) with an unexposed group (where the factor is absent). This comparison can be quantified using three key measures: Risk Difference (RD): The absolute difference in disease risk between the exposed and unexposed groups. Relative Risk (RR): The ratio of disease risk in the exposed group to that in the unexposed group. Odds Ratio (OR): The ratio of the odds of disease in the exposed group to the odds in the unexposed group. While risk reflects the proportion of individuals affected within a population, odds represent the ratio of affected to unaffected individuals. The OR is particularly useful in case-control studies because it can approximate the RR when diseases are rare, providing valuable insights even when direct risk calculations are not feasible.
- Open Access
- 26 February 2024
- Published by Sociedad Espanola de Quimioterapia in Revista Española de Quimioterapia
- Vol. 37 (3) , 203-208
Clinical study types and guidance for their correct post-pandemic interpretation
Randomized clinical trials (RCTs) are key to the advancement of medicine and microbiology, but they are not the only option. Observational studies provide information on long-term efficacy and safety, are less expensive, allow the study of rare events, and obtain information more quickly than RCTs. On the other hand, they are more vulnerable to confounding factors. Prospective exploratory pilot studies share many aspects with RCTs but are not subject to supervision by external commissions or mandatory registration. Multitesting can pervert the balance of publications in favor of the desired effect. Bonferroni's reasoning shows that if 10 studies are performed with an ineffective antibiotic, the probability that at least one will show P 0.05) are not published, the scientific community would consider that there is strong evidence in favor of its usefulness. In conclusion, RCTs are a very good source of clinical information, but are not the only one. The systematic registration of all research can and should be applied to all types of clinical studies.
- 26 February 2024
- Published by Sociedad Espanola de Quimioterapia in Revista Española de Quimioterapia
- Vol. 37 (3) , 203-208
Open AccessClinical study types and guidance for their correct post-pandemic interpretation
Randomized clinical trials (RCTs) are key to the advancement of medicine and microbiology, but they are not the only option. Observational studies provide information on long-term efficacy and safety, are less expensive, allow the study of rare events, and obtain information more quickly than RCTs. On the other hand, they are more vulnerable to confounding factors. Prospective exploratory pilot studies share many aspects with RCTs but are not subject to supervision by external commissions or mandatory registration. Multitesting can pervert the balance of publications in favor of the desired effect. Bonferroni's reasoning shows that if 10 studies are performed with an ineffective antibiotic, the probability that at least one will show P 0.05) are not published, the scientific community would consider that there is strong evidence in favor of its usefulness. In conclusion, RCTs are a very good source of clinical information, but are not the only one. The systematic registration of all research can and should be applied to all types of clinical studies.
- 1 September 2020
- Published by Taylor & Francis in Future Cardiology
- Vol. 17 (4) , 685-692
A new index to predict quality of anticoagulation control in patients on vitamin K antagonists: the DAFNE score
Aim: To derive a new clinical score to improve the prediction of those at risk of poor International Normalized Ratio control among patients with atrial fibrillation taking vitamin K antagonists. Materials & methods: The score was calculated using PAULA database and validated in the FANTASIIA population. Results: The DAFNE score (cardiovascular Disease, concomitant treatment with Amiodarone, Food/dietary transgression and taking >= 7 pills daily, fEemale sex) score was related to a higher probability of poor International Normalized Ratio control. C-indexes were 0.611 and 0.576 (De Long test, p = 0.007) for the DAFNE and SAMe-TT2R2 scores, respectively. Conclusion: The DAFNE score is a new clinical score which may potentially help determine those patients with atrial fibrillation who are at high risk of poor anticoagulation control with vitamin K antagonists.
- 1 September 2020
- Published by Taylor & Francis in Future Cardiology
- Vol. 17 (4) , 685-692
A new index to predict quality of anticoagulation control in patients on vitamin K antagonists: the DAFNE score
Aim: To derive a new clinical score to improve the prediction of those at risk of poor International Normalized Ratio control among patients with atrial fibrillation taking vitamin K antagonists. Materials & methods: The score was calculated using PAULA database and validated in the FANTASIIA population. Results: The DAFNE score (cardiovascular Disease, concomitant treatment with Amiodarone, Food/dietary transgression and taking >= 7 pills daily, fEemale sex) score was related to a higher probability of poor International Normalized Ratio control. C-indexes were 0.611 and 0.576 (De Long test, p = 0.007) for the DAFNE and SAMe-TT2R2 scores, respectively. Conclusion: The DAFNE score is a new clinical score which may potentially help determine those patients with atrial fibrillation who are at high risk of poor anticoagulation control with vitamin K antagonists.
- 23 January 2019
- Published by Bentham Science Publishers Ltd. in Cardiovascular & Hematological Agents in Medicinal Chemistry
- Vol. 16 (2) , 106-113
Perception of Patients Regarding Burdens and Benefits of Vitamin K Antagonists Among Patients with Nonvalvular Atrial Fibrillation
Background: Achieving a good satisfaction with anticoagulant treatment should be a target in Atrial Fibrillation (AF) patients. Objective: To ascertain the perception of patients regarding burdens and benefits of anticoagulation with Vitamin K Antagonists (VKA). Methods: This was a multicenter cross-sectional/retrospective study conducted throughout Spain, in which AF patients taking VKA during the last year, attended at primary care setting were included. The Anti-Clot-Treatment Scale (ACTS) was used to determine perceived burdens and benefits with anticoagulation. Results: Overall, 1,386 patients (mean age 77.4 ± 8.7 years; 48.6% women; 64.2% permanent AF; CHA2DS2-VASc 3.9 ± 1.5; HAS-BLED 1.6 ± 0.9) were analyzed. The adequate anticoagulation control was achieved by 56.9/60.6% of patients according to direct method/Rosendaal method, respectively. Overall, mean ACTS Burdens scale score was 49.4 ± 8.8 and mean ACTS Benefits scale score 11.2 ± 2.2. Active patients, polymedication, elderly and visits to the nurse were associated with higher scores in the ACTS Burdens scale (lower perceived burden), whereas visits to the emergency department and primary care physician were associated with lower scores in the ACTS Burdens scale (higher perceived burden). Active patients, number of INR determinations, visits to the nurse, and an adequate INR control were associated with higher scores in the ACTS Benefits scale (higher perceived benefit), whereas visits to the emergency department and to the primary care physician were associated with lower scores in the ACTS Benefits scale (lower perceived benefit). Conclusion: Satisfaction with treatment was high among patients with AF chronically anticoagulated with VKA, suggesting that quality of life is not impaired in this population.
- 23 January 2019
- Published by Bentham Science Publishers Ltd. in Cardiovascular & Hematological Agents in Medicinal Chemistry
- Vol. 16 (2) , 106-113
Perception of Patients Regarding Burdens and Benefits of Vitamin K Antagonists Among Patients with Nonvalvular Atrial Fibrillation
Background: Achieving a good satisfaction with anticoagulant treatment should be a target in Atrial Fibrillation (AF) patients. Objective: To ascertain the perception of patients regarding burdens and benefits of anticoagulation with Vitamin K Antagonists (VKA). Methods: This was a multicenter cross-sectional/retrospective study conducted throughout Spain, in which AF patients taking VKA during the last year, attended at primary care setting were included. The Anti-Clot-Treatment Scale (ACTS) was used to determine perceived burdens and benefits with anticoagulation. Results: Overall, 1,386 patients (mean age 77.4 ± 8.7 years; 48.6% women; 64.2% permanent AF; CHA2DS2-VASc 3.9 ± 1.5; HAS-BLED 1.6 ± 0.9) were analyzed. The adequate anticoagulation control was achieved by 56.9/60.6% of patients according to direct method/Rosendaal method, respectively. Overall, mean ACTS Burdens scale score was 49.4 ± 8.8 and mean ACTS Benefits scale score 11.2 ± 2.2. Active patients, polymedication, elderly and visits to the nurse were associated with higher scores in the ACTS Burdens scale (lower perceived burden), whereas visits to the emergency department and primary care physician were associated with lower scores in the ACTS Burdens scale (higher perceived burden). Active patients, number of INR determinations, visits to the nurse, and an adequate INR control were associated with higher scores in the ACTS Benefits scale (higher perceived benefit), whereas visits to the emergency department and to the primary care physician were associated with lower scores in the ACTS Benefits scale (lower perceived benefit). Conclusion: Satisfaction with treatment was high among patients with AF chronically anticoagulated with VKA, suggesting that quality of life is not impaired in this population.
- 1 December 2015
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 68 (12) , 1181-1182
Control de la anticoagulación con warfarina o acenocumarol en España. ¿Hay diferencias?
- 1 December 2015
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 68 (12) , 1181-1182
Control de la anticoagulación con warfarina o acenocumarol en España. ¿Hay diferencias?
- 9 February 2004
- Published by Wiley in Birth Defects Research Part A: Clinical and Molecular Teratology
- Vol. 70 (2) , 75-81
Secular decreasing trend of the frequency of hypospadias among newborn male infants in Spain
BACKGROUND: The frequency of hypospadias is not uniform worldwide. Several countries have reported an increase in its frequency at birth. Although a better ascertainment of the minor forms has been considered as an explanation, the potential effect of environmental endocrine disrupters has also been proposed. We studied the secular trend of hypospadias in Spain over the past 22 years, separating the minor and major forms.METHODS: We used data from the Spanish Collaborative Study of Congenital Malformations (ECEMC) registry, analyzing the frequency in two different periods: from 1978 to 1995, and from 1996 to 2002. To evaluate the “step” of the frequency between the two periods, we applied a parametric Student's t‐test, and the nonparametric Mann‐Whitney rank test.RESULTS: The birth frequency of isolated and total hypospadias was quite stable between 1978 and 1995. In 1996, it decreased dramatically in a step, essentially due to isolated cases with minor forms of hypospadias. Study of the geographical distribution by the 17 Spanish regions showed that the frequency step occurred in nearly all of them.CONCLUSIONS: It is difficult to consider that the observed decrease of the frequency of minor forms of hypospadias could be due to less accurate reporting of these minor forms in all 87 hospitals in the same year without any previous physician agreement. This decrease rather suggests a change in some product or exposure affecting the whole country. We think that the observed change in the frequency cannot be attributable to a lower exposure to endocrine disrupters or the voluntary interruption of gestation. Birth Defects Research (Part A) 67:000–000, 2003.
- 9 February 2004
- Published by Wiley in Birth Defects Research Part A: Clinical and Molecular Teratology
- Vol. 70 (2) , 75-81
Secular decreasing trend of the frequency of hypospadias among newborn male infants in Spain
BACKGROUND: The frequency of hypospadias is not uniform worldwide. Several countries have reported an increase in its frequency at birth. Although a better ascertainment of the minor forms has been considered as an explanation, the potential effect of environmental endocrine disrupters has also been proposed. We studied the secular trend of hypospadias in Spain over the past 22 years, separating the minor and major forms.METHODS: We used data from the Spanish Collaborative Study of Congenital Malformations (ECEMC) registry, analyzing the frequency in two different periods: from 1978 to 1995, and from 1996 to 2002. To evaluate the “step” of the frequency between the two periods, we applied a parametric Student's t‐test, and the nonparametric Mann‐Whitney rank test.RESULTS: The birth frequency of isolated and total hypospadias was quite stable between 1978 and 1995. In 1996, it decreased dramatically in a step, essentially due to isolated cases with minor forms of hypospadias. Study of the geographical distribution by the 17 Spanish regions showed that the frequency step occurred in nearly all of them.CONCLUSIONS: It is difficult to consider that the observed decrease of the frequency of minor forms of hypospadias could be due to less accurate reporting of these minor forms in all 87 hospitals in the same year without any previous physician agreement. This decrease rather suggests a change in some product or exposure affecting the whole country. We think that the observed change in the frequency cannot be attributable to a lower exposure to endocrine disrupters or the voluntary interruption of gestation. Birth Defects Research (Part A) 67:000–000, 2003.
- 1 February 2001
- Published by S. Karger AG in Neuroendocrinology
- Vol. 73 (2) , 111-122
Estrogen Modulates α1/β-Adrenoceptor- Induced Signaling and Melatonin Production in Female Rat Pinealocytes
Nocturnal rise in pineal melatonin output is due to the night-induced acceleration of noradrenergic transmission and α1- and β-adrenoceptor activation. In addition, in female animals, cyclic oscillations in circulating levels of sex steroid hormones are accompanied by changes in the rate of pineal melatonin secretion. To investigate whether estrogen directly affects pineal adrenoceptor responsiveness, pinealocytes from 21-day-old ovariectomized rats were exposed to physiological concentrations of 17β-estradiol (17β-E2) and treated with noradrenergic agonists. Direct exposure to 17β-E2 reduced α1/β-adrenoceptor-induced stimulation of melatonin synthesis and release. This effect was mediated by an estrogen-dependent inhibition of both β-adrenoceptor-induced accumulation of cAMP and α1-adrenoceptor-induced phosphoinositide hydrolysis. Furthermore, estrogen reduced transient Ca2+ signals elicited in single pinealocytes by α1-adrenoceptor activation or by potassium-induced depolarization. In the case of β-adrenoceptor responsiveness, neither forskolin- nor cholera toxin-induced accumulation of cAMP were affected by previous exposure to 17β-E2. This indicates that estrogen effects must be exerted upstream from adenylylcyclase activation, and independent of modifications in G protein expression, therefore suggesting changes in either adrenoceptor expression or receptor-effector coupling mechanisms. Since estrogen effects upon adrenoceptor responsiveness in pineal cells was not mimicked by 17β-E2 coupled to bovine serum albumin and showed a latency of 48 h, this effect could be compatible with a genomic action mechanism. This is also consistent with the presence of two estrogen receptor proteins, α- and β-subtypes, in female rat pinealocytes under the present experimental conditions.
- 1 February 2001
- Published by S. Karger AG in Neuroendocrinology
- Vol. 73 (2) , 111-122
Estrogen Modulates α1/β-Adrenoceptor- Induced Signaling and Melatonin Production in Female Rat Pinealocytes
Nocturnal rise in pineal melatonin output is due to the night-induced acceleration of noradrenergic transmission and α1- and β-adrenoceptor activation. In addition, in female animals, cyclic oscillations in circulating levels of sex steroid hormones are accompanied by changes in the rate of pineal melatonin secretion. To investigate whether estrogen directly affects pineal adrenoceptor responsiveness, pinealocytes from 21-day-old ovariectomized rats were exposed to physiological concentrations of 17β-estradiol (17β-E2) and treated with noradrenergic agonists. Direct exposure to 17β-E2 reduced α1/β-adrenoceptor-induced stimulation of melatonin synthesis and release. This effect was mediated by an estrogen-dependent inhibition of both β-adrenoceptor-induced accumulation of cAMP and α1-adrenoceptor-induced phosphoinositide hydrolysis. Furthermore, estrogen reduced transient Ca2+ signals elicited in single pinealocytes by α1-adrenoceptor activation or by potassium-induced depolarization. In the case of β-adrenoceptor responsiveness, neither forskolin- nor cholera toxin-induced accumulation of cAMP were affected by previous exposure to 17β-E2. This indicates that estrogen effects must be exerted upstream from adenylylcyclase activation, and independent of modifications in G protein expression, therefore suggesting changes in either adrenoceptor expression or receptor-effector coupling mechanisms. Since estrogen effects upon adrenoceptor responsiveness in pineal cells was not mimicked by 17β-E2 coupled to bovine serum albumin and showed a latency of 48 h, this effect could be compatible with a genomic action mechanism. This is also consistent with the presence of two estrogen receptor proteins, α- and β-subtypes, in female rat pinealocytes under the present experimental conditions.